Navigation Links
New asthma research opposes current drug treatment, says UH prof
Date:1/26/2009

HOUSTON Just when the Food and Drug Administration is reconsidering the use of stimulants to treat asthma, a new research study offers further evidence to support a University of Houston professor's theory that an opposite approach to asthma treatment may be in order.

Richard A. Bond, professor of pharmacology at the University of Houston College of Pharmacy (UHCOP), has been investigating whether beta-2 adrenoreceptor antagonist drugs (or beta blockers) ultimately might be a safer, more effective strategy for long-term asthma management than the currently used beta-2 adrenoreceptor agonists (or stimulants).

The beta-2 adrenoreceptor is a receptor found in many cells, including the smooth muscle lining the airways, and has long been a target for asthma drugs. However, a recent study shows the absence of asthma-like symptoms in a mouse model that lacks the key gene that produces the receptor. This lends further evidence to Bond's theory that questions whether the pharmaceutical industry should be working to block or inhibit the receptor instead of the current approach of chronically stimulating it to reduce asthma symptoms.

The study, "Beta2-Adrenoreceptor Signaling is Required for the Development of an Asthma Phenotype in a Murine Model," is in the current online issue of the journal Proceedings of the National Academy of Sciences (PNAS), one of the world's most-cited multidisciplinary scientific serials. A follow-up commentary by an independent scientist in the field also will be published in the print issue of PNAS in February.

The timely release of this study comes on the heels of the FDA considering a renewed look at the use of long-acting beta agonist drugs (LABAs) at least those used alone, without a steroidal component for the management of asthma symptoms. In an FDA report released in December, an analysis of more than 100 trials on four drugs (two LABAs alone and two LABA/corticost
'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Pregnant women with asthma can be more confident about some medicines
2. RSV may hide in the lungs, lead to asthma, UT Southwestern researchers report
3. More findings on gene involved in childhood asthma
4. Athletes sweat and tears linked to asthma
5. Asthma monitoring on the Web
6. Asthma and other allergies tied to absence of specialized cells
7. Consumption of nut products during pregnancy linked to increased asthma in children
8. For some who have lost their sense of smell, a once popular asthma drug could help
9. Increased allergen levels in homes linked to asthma
10. Severe asthma may be a different form of the disease
11. HATS off to combat asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... explored the type and number of connections in transcription ... on robustness in a study published in PLOS ... that the assortativity signature contributes to a network,s resilience ... varying the out-out assortativity of TFN models has a ... other three types of assortativity," said Dov A. Pechenick, ...
(Date:8/29/2014)... - In a cell,s nucleus, chromosomal DNA is ... an amalgam biologists call chromatin. Until about two ... "sidekick," the mere packing material around which the ... have developed a greater appreciation for how DNA/histone ... from multiple research institutions studying the sequence of ...
Breaking Biology News(10 mins):Factor in naked mole rat's cells enhances protein integrity 2Assortativity signatures of transcription factor networks contribute to robustness 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
... the Vladimir N. Ipatieff Professor of Catalytic Chemistry, and ... was awarded the Dreyfus Prize in the Chemical Sciences ... Northwestern University. The Dreyfus prize consists of a ... It is awarded biennially by the Camille and Henry ...
... National Institutes of Health-funded personalized drug development center in ... Research Translation awarded to Children,s National Medical Center, University ... to accelerate R&D Washington, DC The first ... development for Duchenne muscular dystrophy (DMD), has been created ...
... at The University of Nottingham are developing microscopic ... generation of breakthrough treatments for currently incurable diseases ... from fat found in the membrane of naturally ... of medical applications, including the potential to detect ...
Cached Biology News:Tobin Marks awarded Dreyfus Prize in the Chemical Sciences 2First NIH-funded personalized drug development center in US will focus on muscle disease 2First NIH-funded personalized drug development center in US will focus on muscle disease 3Organic medical imaging system to detect disease and track medication 2
(Date:8/31/2014)... Texas (PRWEB) August 31, 2014 ... Polyacrylamide Industry” is a professional and in-depth ... report provides basic Polyacrylamide information, including Polyacrylamide ... as well as industry overview. This research ... market as well as global industry analysis ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... A major challenge before new biotechnology start-up ... of Boston-Cambridge, is gaining visibility that can lead to ... Director of Boston’s Adult Stem Cell Technology Center, LLC ... of his company an important priority since he started ... a social media marketing campaign launched earlier ...
Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... Immune Design Corp. (IDC), a privately held biotechnology ... disease, cancer and allergy, announced today that it ... Sanofi-Aventis to investigate the use of IDC,s Glucopyranosyl ... (TLR-4) agonist, in the field of allergy. ...
... 25, 2011 Sangamo BioSciences, Inc. (Nasdaq: SGMO ... For the third quarter ended September 30, ... or $0.18 per share, compared to a net loss of ... in 2010. As of September 30, 2011, the Company had ...
... Graduate Institute (KGI) Research Professor James M. Cregg, PhD, will ... from February 23 – March 3 in Alpbach, Austria. ... development and use of the yeast species, Pichia pastoris ... At the Pichia 2012 Conference he will discuss ...
Cached Biology Technology:Sangamo BioSciences Reports Third Quarter 2011 Financial Results 2Sangamo BioSciences Reports Third Quarter 2011 Financial Results 3Sangamo BioSciences Reports Third Quarter 2011 Financial Results 4Sangamo BioSciences Reports Third Quarter 2011 Financial Results 5Sangamo BioSciences Reports Third Quarter 2011 Financial Results 6KGI Professor Cregg to Be Featured Speaker at Pichia 2012 Conference 2
... Microarrays designed for proteomic scale kinase ... and drug discovery research built on the ... platform. These microarrays are available as part ... Peptide Microarray Service. Probe Content ...
... (Ruggedized Advanced Pathogen Identification Device) is ... for field hospitals, mobile laboratories and ... its ruggedness, it is designed with ... the LightCycler instrument. By taking advantage ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... as a carrier in nucleic ... form: Solution in 10 mM ... mM EDTA Preparation Note: Phenol-chloroform ... Concentration: 10 mg/mL Physical ...
Biology Products: